Introduction {#section1-2058-5241.1.160014}
============

Large-head metal-on-metal (MoM) bearings were re-popularised in the late 1990s with the introduction of modern hip resurfacing (HR), followed shortly afterward by large metal head total hip arthroplasty (THA). The introduction of MoM articulations led to a worldwide increase in the use of MoM hip arthroplasty, which subsequently saw a sharp decline. MoM was rapidly adopted in the early 2000s until adverse reports in the literature led to medical device alerts which were issued by government regulatory agencies and national and international organisations, leading to post-marketing surveillance and the discontinuation of these implants.^[@bibr1-2058-5241.1.160014]-[@bibr3-2058-5241.1.160014]^ It is estimated that more than one million large-head MoM hips have been implanted to date. MoM arthroplasties are among the least successful modern hip implants.^[@bibr4-2058-5241.1.160014]^

As a result of safety concerns, several health authorities, scientific organisations and research groups have published recommendations for their use and follow-up. The British Hip Society advised that, as of 2011, large-stemmed MoM primary THA (excluding HR) should no longer be performed.^[@bibr5-2058-5241.1.160014]^ In 2012 the Dutch Orthopaedic Association was the first nationwide society to suspend the use of all large-head (\> 36 mm) MoM articulations; this advice has since been followed by several societies, including the European Federation of National Associations of Orthopaedics and Traumatology (EFORT).^[@bibr6-2058-5241.1.160014],[@bibr7-2058-5241.1.160014]^ These concerns led the European Commission to ask for the opinion of the Scientific Committee on Emerging and Newly-Identified Health Risks (SCENIHR) regarding the safety of MoM implants.^[@bibr8-2058-5241.1.160014]^

Guidelines for follow-up of these implants differ considerably between regulatory authorities worldwide, which can be attributed to missing or conflicting evidence.^[@bibr9-2058-5241.1.160014]^

A number of studies have recently been published which may assist in defining the use of MoM bearings. Registry data reports a disappointing survival rate ranging between 56.7% and 88.9% at ten years, depending on implant design of large-diameter MoM THA.^[@bibr10-2058-5241.1.160014],[@bibr11-2058-5241.1.160014]^ All available guidelines seem to agree that large-diameter MoM THA should not be used at present, and patients should remain under regular clinical surveillance.^[@bibr1-2058-5241.1.160014]^

A more fierce debate surrounds the use of MoM HR. Long-term results of modern MoM HR are more encouraging, with overall survival rates reported by the developers as well as independent surgeons ranging between 87.1% and 95.8% at 15 years.^[@bibr10-2058-5241.1.160014]^ Registry data on survival of some types of MoM HR arthroplasties are sufficient, according to the guidelines of the National Institute for Health and Clinical Excellence.^[@bibr12-2058-5241.1.160014]^

In this review we describe the outcomes and problems of MoM implant usage, and why these implants are now considered to be unacceptable.

Two different implants {#section2-2058-5241.1.160014}
======================

There are two different types of large-head MoM hip prostheses: MoM HR and MoM THA (see [Figs 1](#fig1-2058-5241.1.160014){ref-type="fig"} and [2](#fig2-2058-5241.1.160014){ref-type="fig"}). Both types were designed with young and active patients in mind. Purported advantages over conventional polyethylene articulations were low wear rates, increased range of motion (with increasing head size), and improved stability and reduced dislocation rates,^[@bibr13-2058-5241.1.160014]^ although these merits have been debated. An estimated 35% of all hip arthroplasties performed in the US between 2005 and 2006 involved large head MoM implants.^[@bibr14-2058-5241.1.160014]^ In 2008, the UK National Joint Registry (NJR) recorded a peak in the use of MoM implants.^[@bibr15-2058-5241.1.160014]^ The use of HR has been advocated ahead of THA due to several apparent advantages: preservation and conservation of bone stock on the femoral side (but not the acetabular side);^[@bibr16-2058-5241.1.160014]-[@bibr20-2058-5241.1.160014]^ easier replication of biomechanics and limb length; and the absence of modular components with a taper.^[@bibr21-2058-5241.1.160014]^ Both types have the advantage of reducing the risk of dislocation associated with the use of increasing head size when compared with conventional heads and a supposedly increased range of motion.^[@bibr4-2058-5241.1.160014]^

![Hip resurfacing: Birmingham hip resurfacing system (Smith & Nephew; Andover, Massachusetts).](eor-1-345-g001){#fig1-2058-5241.1.160014}

![Retrieval of total hip resurfacing, Bi-Metric TM stem with the M2a Magnum TM components (Biomet; Warsaw, Indiana).](eor-1-345-g002){#fig2-2058-5241.1.160014}

Registry data suggest that MoM total hip arthroplasties fail at a higher rate than conventional THA using other bearing materials.^[@bibr22-2058-5241.1.160014]^ Limitations in the interpretation of registry data are indication bias and the clustering of different MoM devices. Design differences are often ignored in registries and data regarding component positioning are typically unavailable.^[@bibr21-2058-5241.1.160014]^ [Table 1](#table1-2058-5241.1.160014){ref-type="table"} lists survival percentages for the different hip arthroplasties as reported by the four largest implant registries.^[@bibr23-2058-5241.1.160014]-[@bibr26-2058-5241.1.160014]^

###### 

Ten-year survival rate (%) and number of THA osteoarthritis at risk from the annual reports of full ISAR members

                                                             Cemented                                                       Uncemented                                                     All hybrid                                                     MoM THA                                                        HRA                                                            HRA BHR                                                                                                                                                                                                                
  ---------------------------------------------- ----------- -------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------- -------- -------------------------------------------------------------- -------- -------------------------------------------------------------- -------- ------
  Sweden 2012^[@bibr23-2058-5241.1.160014]^                  98.0                                                           \_                                                             98.8                                                           \_                                                             96.6[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   \_                                                            \_       \_                                                             95.1     \_                                                             \_       \_
                                                 123 012     91 055                                                                                                                        16 241                                                                                                                        14 916                                                                                                                                                                                               800                                                                              
  Australia 2014^[@bibr24-2058-5241.1.160014]^               94.0                                                           91.5                                                           94.6                                                           94.4                                                           95.2                                                           93.2                                                          82.6     81.5                                                           90.0     89.3                                                           93.0     92.8
                                                 275 829     19 695                                                         775                                                            136 311                                                        19 116                                                         77 768                                                         3927                                                          3627     955                                                            4747     2535                                                           4161     2212
  Denmark 2013^[@bibr25-2058-5241.1.160014]^                 93.5                                                           87.1[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   93.7                                                           92.6[†](#table-fn2-2058-5241.1.160014){ref-type="table-fn"}    91.5                                                           87.6[†](#table-fn2-2058-5241.1.160014){ref-type="table-fn"}   89.0     \_                                                                      \_                                                             94.0     \_
                                                 80 816      29 375                                                         163                                                            14 936                                                         11 158                                                         17 186                                                         3079                                                          4646                                                                                                                                            273      
  NJR 2014^[@bibr26-2058-5241.1.160014]^                     96.9[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   93.2[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   95.8[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   94.8[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   96.5[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   95.0                                                          80.1     75.5[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   84.4     86.7[\*](#table-fn1-2058-5241.1.160014){ref-type="table-fn"}   90.6     \_
                                                 683 868     226 226                                                        745                                                            211 429                                                        32 771                                                         113 215                                                        9731                                                          30 175   5567                                                           17 535   17 547                                                         18 927   
  Total (%)                                                  96.7                                                           91.5                                                           95.3                                                           94.3                                                           95.7                                                           93.2                                                          81.5     76.5                                                           84.9     87.1                                                           91.5     92.8
                                                 1 163 525   366 351                                                        1683                                                           378 917                                                        63045                                                          223 085                                                        16 737                                                        38 448   6522                                                           23 082   20 082                                                         23 361   2212

data acquired through calculation

age \<60

THA, total hip arthroplasty; ISAR, International Society of Arthroplasty Registers; NJR, National Joint Registry; MoM THA, metal-on-metal total hip arthroplasty; HRA, hip resurfacing arthroplasty; HRA BHR, hip resurfacing arthroplasty Birmingham Hip Resurfacing

Problems with MoM hip arthroplasty {#section3-2058-5241.1.160014}
==================================

Problems reported with MoM HR and large-head MoM THA initially concerned raised blood cobalt and chromium ions,^[@bibr27-2058-5241.1.160014]^ loosening of components,^[@bibr28-2058-5241.1.160014]^ soft-tissue reactions around the hip^[@bibr29-2058-5241.1.160014]^ and osteolysis.^[@bibr30-2058-5241.1.160014]^ Wear at the ball and socket interface as well as modularity at the head---neck junction and taper adaptors in MoM THA can be an important source of metal ions. Wear at the ball and socket is influenced by component positioning; in some studies, taper-head wear also seems to be influenced by wear at the ball---socket interface.^[@bibr28-2058-5241.1.160014]^

Some authors report excellent results with MoM HR devices. Well-designed components implanted within strict parameters, the knowledge of the surgeon and analysis of recently published research could contribute to an increasing understanding of the problems with large-head hip arthroplasties.^[@bibr21-2058-5241.1.160014]^

Local tissue reactions {#section4-2058-5241.1.160014}
======================

By generating metal debris, MoM hip arthroplasty can cause the formation of peri-articular masses referred to as pseudotumours. These are non-neoplastic and non-infective lesions situated in various locations in the peri-prosthetic tissue.^[@bibr31-2058-5241.1.160014],[@bibr32-2058-5241.1.160014]^ A pseudotumour is referred to more specifically as an adverse reaction to metal debris (ARMD), and more generally as an adverse local tissue reaction (ALTR). The term 'aseptic lymphocytic vasculitis-associated lesion' (ALVAL) is reserved for histological findings;^[@bibr33-2058-5241.1.160014]^ the term 'metallosis' should be avoided for these cases.

Pseudotumours can be solid, cystic lesions that have a direct communication with the joint.^[@bibr31-2058-5241.1.160014]^ The described terminology can be confusing in the literature as there is inconsistency in its use. Imaging, operative and histopathological findings are used to describe the same phenomenon.^[@bibr34-2058-5241.1.160014]^ In most documented cases, metal wear particles have been found histologically.^[@bibr35-2058-5241.1.160014]^ The incidence of pseudotumours depends on the definition used and the type of pseudotumour, and their prevalence is estimated to be from 3% to over 60% ([Table 2](#table2-2058-5241.1.160014){ref-type="table"}) for both well- and poorly-functioning MoM hips.^[@bibr34-2058-5241.1.160014],[@bibr36-2058-5241.1.160014]-[@bibr50-2058-5241.1.160014]^ To date, it is not clear which implant type has the highest risk for development of a pseudotumour. Again, the large variety in data, pseudotumour definitions and diagnostic imaging techniques limit the successful evaluation of the information.

###### 

Incidence of pseudotumour and acute lymphocytic vasculitis associated lesion (ALVAL) reactions in metal-on-metal hip articulations[\*](#table-fn4-2058-5241.1.160014){ref-type="table-fn"}

  Citation                                        Type of implant   Company                     MoM type   Pseudotumour or ALVAL   \%
  ----------------------------------------------- ----------------- --------------------------- ---------- ----------------------- ------
  Bosker 2012^[@bibr36-2058-5241.1.160014]^       M2A               Biomet                      THA        42/108                  38.8
  Hasegawa 2014^[@bibr37-2058-5241.1.160014]^     Cormet            Corin                       THA        24/108                  22.2
  Bayley 2015^[@bibr38-2058-5241.1.160014]^       M2A               Biomet                      THA        38/191                  19.8
  Hasegawa 2014^[@bibr37-2058-5241.1.160014]^     Pinnacle          DePuy                       THA        12/80                   15.0
  Korovessis 2006^[@bibr39-2058-5241.1.160014]^   Sikomet SM21      Plus Rotkreuz Orthopedics   THA        14/217                  6.4
  Zijlstra 2010^[@bibr40-2058-5241.1.160014]^     Stanmore MoM      Biomet                      THA        1/42                    2.3
  Latteier 2011^[@bibr41-2058-5241.1.160014]^     M2A               Biomet                      THA        17/1212                 1.4
  Park 2005^[@bibr42-2058-5241.1.160014]^         S-rom             DePuy                       THA        2/169                   1.1
  Saito 2010^[@bibr43-2058-5241.1.160014]^        Metasul           Zimmer                      THA        0/90                    0
  Wagner 1996^[@bibr44-2058-5241.1.160014]^       Metasul           Zimmer                      THA        0/70                    0
  Chang 2013^[@bibr45-2058-5241.1.160014]^        ASR               DePuy                       HR         107/156                 68.5
  Bisschop 2013^[@bibr46-2058-5241.1.160014]^     BHR               Smith & Nephew              HR         40/143                  27.9
  Carrothers 2010^[@bibr47-2058-5241.1.160014]^   BHR               Smith & Nephew              HR         15/5000                 0.3
  Malviya 2009^[@bibr48-2058-5241.1.160014]^      BHR               Smith & Nephew              HR         1/670                   0.1
  Malviya 2011^[@bibr49-2058-5241.1.160014]^      BHR               Smith & Nephew              HR         0/50                    0
  Smolders 2011^[@bibr50-2058-5241.1.160014]^     Conserve plus     Wright Medical Technology   HR         0/43                    0
  Wagner 1996^[@bibr44-2058-5241.1.160014]^       Metasul           Zimmer                      HR         0/35                    0

Reprinted from J Arthroplasty, Incidence of pseudotumor and acute lymphocytic vasculitis associated lesion (ALVAL) reactions in metal-on-metal hip articulations: a meta-analysis. Ding K, Stoner JA, Teague DC, Yousuf KM.2013;28:1238-1245. Wiith permission from Elsevier.

MoM, metal-on-metal; ALVAL, aseptic lymphocyte-dominated vasculitis-associated lesion; M2A, Magnum hip replacement; ASR, acetabular hip system; BHR, Birmingham hip resurfacing; THA, total hip arthroplasty; HR, hip resurfacing

Metal ion levels {#section5-2058-5241.1.160014}
================

It is generally accepted that MoM HR and THA lead to increased whole blood levels of chromium (Cr) and cobalt (Co).^[@bibr51-2058-5241.1.160014]^ Besides the local effect of metal debris, there are concerns about possible systemic toxic effects as impaired renal function, immune modulation, hypersensitivity, chromosomal damage, malignant cellular transformation, neuropathy, cardiomyopathy and thyroid function disorders are reported.^[@bibr52-2058-5241.1.160014]-[@bibr55-2058-5241.1.160014]^ Causal associations between MoM bearings and potential risks have not yet been established, and neither have safe levels for metal ions.^[@bibr56-2058-5241.1.160014]^

Controversy remains regarding the need for metal ion analysis.There is in fact no international consensus as to whether chromium and/or cobalt should even be monitored.^[@bibr57-2058-5241.1.160014]^ Threshold ion levels for orthopaedic implants are provided by several authors, organisations and committees.^[@bibr58-2058-5241.1.160014]^ Median ion levels and acceptable ranges corresponding with well- or insufficiently-functioning MoM implants are reported.^[@bibr59-2058-5241.1.160014]-[@bibr61-2058-5241.1.160014]^

Recent studies have tried to provide a more precise threshold level for cobalt in unilaterally-operated patients with additional information on sensitivity and specificity.^[@bibr60-2058-5241.1.160014],[@bibr62-2058-5241.1.160014]-[@bibr67-2058-5241.1.160014]^ End points differ considerably between these studies:^[@bibr68-2058-5241.1.160014]^ the specificity for predicting a poor clinical result is sometimes high while sensitivity is uniformly low. Metal ions only seem to adequately predict the presence of volumetric wear, and a metal ions trend may be more predictive of bearing malfunction than a single measurement.^[@bibr69-2058-5241.1.160014]^ Given these observations, institutional recommendations for a specific safe cut-off level or threshold for further investigation become questionable. Other studies also demonstrate that there is not enough evidence for precise threshold levels of metal ions as a trigger for intervention, or to predict adverse systemic effects for an individual patient.^[@bibr57-2058-5241.1.160014],[@bibr70-2058-5241.1.160014],[@bibr71-2058-5241.1.160014]^

In 2012 the UK Medicines and Healthcare Products Regulatory Agency (MHRA) adopted a 7 µg/L blood level for their medical advice alert. Above this level, additional investigations are recommended, including cross-sectional imaging.^[@bibr1-2058-5241.1.160014]^ In a January 2013 safety communication on MoM hip implants, the US Food and Drug Administration (FDA) did not define a threshold level as a trigger for revision or any other medical intervention. The American Academy of Orthopaedic Surgeons defines three groups in a stratification scheme. The cut-off points mentioned in this scheme are \< 3 µg/L for the low-risk group metal ion level, 3-10 µg/L for the medium-risk group and \> 10 µg/L for the high-risk group.

In their consensus statement on management of MoM bearings, EFORT, the European Hip Society (EHS), the Arbeidsgemeinschaft Endoprothetik (AE) and the Deutsche Arthrosehilfe (DAH) use two cobalt levels; levels without clinical concern are \< 2 µg/L and a threshold value for clinical concern, is within the range of 2 to 7 µg/L.^[@bibr5-2058-5241.1.160014],[@bibr6-2058-5241.1.160014],[@bibr8-2058-5241.1.160014]^ The 2011 Dutch Orthopaedic Association (NOV) advice on MoM hip implants showed four cut-off points: normal at \< 2µg/L, slightly elevated at between 2 and 4 µg/L, elevated above 4 µg/L and extremely elevated at \> 20 µg/L.^[@bibr7-2058-5241.1.160014]^ The Agence Francaise de Securité Sanitaire des Produits de Santé does not use ion levels in its advice but emphasises clinical and radiological follow-up.^[@bibr70-2058-5241.1.160014]^

There is no obvious consensus in the current literature on threshold levels for metal ions or how to interpret them. In addition, there is not enough data available for bilateral MoM implants. Whether a threshold in the range of between 2 µg/L and 7 µg/L will be determined to differentiate between a well-functioning prosthesis and clinical concern remains to be determined. Moreover, it is unclear whether a maximal acceptable level can be determined above which revision surgery should be considered. There is still insufficient support for values such as the \>20 µg/L level, as suggested by some authors.^[@bibr67-2058-5241.1.160014]^ Metal ion levels should be repeated and their development over time considered. Rather than being a single diagnostic tool, metal ions should be assessed in the entire context of the clinical and radiological findings. MoM HR and THA lead to increased whole blood levels of chromium and cobalt. An analysis of literature by Jantzen^[@bibr72-2058-5241.1.160014]^ did not show a difference in ion concentrations between MoM HR or THA, but the study had major limitations, among them the inclusion of heterogeneous groups of patients and different measurement techniques for ion levels. We must also be aware that there is no precise knowledge on the longer-term effects on the human body of prolonged exposure to even mild elevation of blood metal ions.

Metal artefact reduction sequencing MRI, CT and ultrasound imaging {#section6-2058-5241.1.160014}
==================================================================

Imaging of MoM THA or HR is advised by all authorities, using several imaging modalities to screen and diagnose pseudotumours around a hip arthroplasty. Use of MRI with metal artefact reduction sequencing (MARS) or ultrasound is advocated. At present, MRI is widely used to assess adverse local tissue reactions (ALTR) owing to its advantages of superior imaging contrast for soft-tissue abnormalities and the ready availability of three-dimensional assessment of abnormal lesions.^[@bibr62-2058-5241.1.160014],[@bibr73-2058-5241.1.160014],[@bibr74-2058-5241.1.160014]^ Computed tomography (CT) is also acceptable for the FDA and European agencies ([Fig. 3](#fig3-2058-5241.1.160014){ref-type="fig"}). No consensus exists as to which modality is most effective.^[@bibr9-2058-5241.1.160014]^ As different imaging modalities are under debate, a recent publication suggests that CT is not suitable for routine follow-up for MoM imaging.^[@bibr73-2058-5241.1.160014]^ Improved CT imaging techniques are however currently available.^[@bibr74-2058-5241.1.160014]^ In addition, screening for capsular reactions by means of CT is efficient and relatively quick. In general, availability of CT is higher than MR (especially MARS MRI), and costs are estimated to be between two and four times lower.^[@bibr74-2058-5241.1.160014]^ The additional advantage of CT is that implant positioning can be observed and it is much better in detecting osteolysis.^[@bibr74-2058-5241.1.160014]^ Ultrasound is an effective and attractive screening tool for identifying pseudotumours. It is observer-dependent, however, and only suitable for detecting soft-tissue abnormalities.^[@bibr9-2058-5241.1.160014],[@bibr75-2058-5241.1.160014]^

![CT scan of the axial section of an unilateral metal-on-metal total hip arthroplasty, showing a large pseudotumour anteromedial of the right hip.](eor-1-345-g003){#fig3-2058-5241.1.160014}

Because of the high cost, required waiting and examination times and various contra-indications (e.g. for patients with pacemakers, ferromagnetic haemostatic clips or claustrophobia), MRI may not be the most suitable screening tool for ALTR in a large cohort of patients.^[@bibr74-2058-5241.1.160014]^ Ultrasound examination has advantages over other imaging modalities, including an absence of ionising radiation and metal artefacts, comparatively low cost and its availability for use at follow-up consultations.^[@bibr75-2058-5241.1.160014]^

New developments in imaging techniques such as MARS for MRI and CT such as the O-MAR automatic metal artefact reduction algorithm (Philips; Guildford, Surrey, UK) are available as screening tools for pseudotumours. These techniques are intended to reduce the size and intensity of artefacts such as orthopaedic implants. The Consensus Statement by EFORT and EHS^[@bibr57-2058-5241.1.160014],[@bibr58-2058-5241.1.160014]^ states that ordinary MRI without use of the MARS technique is ineffective. Ultimately the choice should be made based on the availability of high-quality imaging, such as MARS MRI or O-MAR CT together with the availability of an experienced radiologist, the necessity to screen large cohorts of patients and the cost of different modalities, which can vary with different institutions.

Taper issues {#section7-2058-5241.1.160014}
============

Clinical failure of MoM THA may also be related to corrosion of the head---neck junction.^[@bibr76-2058-5241.1.160014]^ The exact mechanism remains unclear.^[@bibr77-2058-5241.1.160014]-[@bibr79-2058-5241.1.160014]^ Joint friction moments in mechanical loading cycles have been suggested to induce relative motion at the interface between modular components, facilitating fretting corrosion as well as removal of the protective oxide layer.^[@bibr77-2058-5241.1.160014],[@bibr79-2058-5241.1.160014]^ This mechanism could explain the rising revision rates of modular MoM bearings with increasing bearing diameter,^[@bibr26-2058-5241.1.160014]^ mainly because the joint friction moment increases with bearing diameter and the tolerance of the taper decreases with its diameter.^[@bibr80-2058-5241.1.160014]^ Small differences in taper angle between adaptor/head and stem tapers facilitate this due to design or manufacturing tolerances.^[@bibr76-2058-5241.1.160014]^ In the search for more stability, with increasing head size and reduced taper diameter, the tolerance of the head---neck junction seems to have failed. Further research is needed to determine the maximum head size to fit different taper diameter tolerances.

Revision {#section8-2058-5241.1.160014}
========

Revision of HR and MoM THA has become increasingly common. To date, few studies have reported on outcomes following revision of HR and MoM THA. There is no consensus on when to revise or how. High complication rates and poor functional outcome are frequently reported after revision of HR and THA.^[@bibr81-2058-5241.1.160014]-[@bibr88-2058-5241.1.160014]^ In a systematic review, Matharu describes complication rates ranging between 4% and 68% and re-revision rates of between 3% and 38%.^[@bibr86-2058-5241.1.160014]^ Complication rates following ARMD revision appear higher than for other revision indications, and according to some authors, the extent of capsular resections makes this comparable to revision for infected arthroplasty.^[@bibr87-2058-5241.1.160014],[@bibr88-2058-5241.1.160014]^

Instability, infection and recurrence of the pseudotumour are the most frequently reported complications. Because of the high recurrence rates of pseudotumours post-revision, use of non-MoM bearings is recommended when revising these patients.^[@bibr82-2058-5241.1.160014],[@bibr83-2058-5241.1.160014],[@bibr87-2058-5241.1.160014]^

Current advice on large head MoM total hip arthroplasties {#section9-2058-5241.1.160014}
=========================================================

Follow-up strategy {#section10-2058-5241.1.160014}
------------------

At the moment there is no international consensus on follow-up for MoM HR or THA. Government regulatory agencies and national and international societies have issued advice for the follow-up of MoM hip arthroplasties. For example, Italian authorities adopted the advice of the EFORT-EHS European consensus statement and the SCENIHR document on the follow-up of patients.^[@bibr89-2058-5241.1.160014]^ Significant differences exist between protocols, which no longer reflect current evidence. Such differences include not stratifying patients according to implant type (THA or HR) or ARMD risk factors, using symptoms to decide on patient follow-up, and using suboptimal blood metal ion thresholds to identify poorly performing hips.^[@bibr1-2058-5241.1.160014],[@bibr2-2058-5241.1.160014],[@bibr6-2058-5241.1.160014],[@bibr7-2058-5241.1.160014],[@bibr8-2058-5241.1.160014]^ Furthermore, variable information is provided by different authorities on the collection, processing and analysis of blood metal ion samples.^[@bibr1-2058-5241.1.160014],[@bibr2-2058-5241.1.160014],[@bibr6-2058-5241.1.160014],[@bibr7-2058-5241.1.160014],[@bibr8-2058-5241.1.160014]^

Patients with large-head MoM hip implants should be monitored according to a comprehensive screening protocol involving clinical results, metal ion levels and radiological follow-up that includes cross-sectional imaging with metal artefact reduction or, alternately, ultrasound.

Follow-up frequency {#section11-2058-5241.1.160014}
-------------------

More information has recently become available regarding the development and progression of ARMD.^[@bibr26-2058-5241.1.160014]^ Asymptomatic MoM-HR patients with normal blood metal ion levels (\<2 μg/L) and normal ultrasound imaging are at very little risk of progression of ultrasound findings (2%), and at minimal risk of developing new pseudotumours (0%) within five years of initial assessment.^[@bibr90-2058-5241.1.160014]^ This sub-group does not require repeat follow-up within five years of initial assessment. Metal ion levels are insufficient as a single screening method for detecting failure of MoM implants; they are most useful as a measure of volumetric wear, and their development over time seems most useful in detecting possible failure of MoM implants.^[@bibr90-2058-5241.1.160014]^

Screening every five years can be considered for asymptomatic patients with a large-head MoM (T)HR *in situ* for at least ten years. An annual follow-up is generally indicated for symptomatic patients at present.

Conclusions {#section12-2058-5241.1.160014}
===========

Discontinuation of use {#section13-2058-5241.1.160014}
----------------------

The future role of MoM HR and THA is uncertain. Some authors report good long-term results for HR^[@bibr21-2058-5241.1.160014]^ and emphasise the role of adequate surgical training, cup positioning and use of reliable HR implants. Unfortunately, bad publicity and the advice of several government regulatory agencies, national and international organisations on MoM hip implants as well as the burden of follow-up for these implants, will make most surgeons and patients reluctant to use them. Medico-legal issues may also play an important role in these decisions. Recently, Smith & Nephew withdrew the 46 diameter and smaller femoral heads from the market for the BHR system and issued new instructions for use that reflect new performance data.^[@bibr91-2058-5241.1.160014]^

The use of large-head MoM THA should be discontinued. MoM HR should be approached with caution and, when considered, used only in patients who satisfy all of the recommended selection criteria, which limit its indications considerably. With alternatives at least equally successful using conventional THA available, even a limited indication for MoM HR is questionable.

Phased introduction of new prosthesis {#section14-2058-5241.1.160014}
-------------------------------------

In its new guidelines for hip prostheses, the Dutch Orthopaedic Association states that any new hip prosthesis under consideration for commercial usage in the Dutch market must pass a phased introduction that includes mandatory radiostereometric (RSA) studies even before larger clinical trials can be initiated.^[@bibr92-2058-5241.1.160014]-[@bibr94-2058-5241.1.160014]^ Lessons from MoM HR and especially MoM THA are incorporated into these guidelines. This phased introduction of new implants or related developments has been proposed by several authors.^[@bibr92-2058-5241.1.160014]-[@bibr95-2058-5241.1.160014]^ The stepwise introduction described by Malchau^[@bibr94-2058-5241.1.160014]^ may be the most widely-known proposal. The phased introduction consists of the these three steps: 1) pre-clinical tests, 2) large clinical trials (ideally multicentre and randomised), and 3) post-marked surveillance in national registries.

The phased introduction of new prostheses should be mandatory in the future. Close monitoring of outcomes and long-term follow-up is also necessary for the introduction of new prostheses.

Gold standard {#section15-2058-5241.1.160014}
-------------

Alternative arthroplasty options with extensive follow-up and excellent results are currently available. Frequently used bearing surfaces and proven head diameters (⩽ 36 mm) with a satisfactory long-term follow-up are :

1.  a ceramic head on a highly cross-linked polyethylene liner;

2.  a metal head on a highly cross-linked polyethylene liner.
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